Lecrolyn (Sodium Cromoglicate)

Sodium cromoglicate stabilizes mast cells on the ocular surface, preventing calcium‑dependent degranulation. By blocking the release of histamine, leukotrienes, and other inflammatory substances, it reduces the allergic response that leads to ocular irritation, swelling, and discharge.

The dosing regimen for Lecrolyn is determined by the prescribing eye‑care professional based on the severity of the allergic condition, patient age, and response to therapy. Patients should follow the specific instructions provided by their ophthalmologist or optometrist.

Safety data for sodium cromoglicate in pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against any unknown risks before prescribing. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Lecrolyn with their doctor.

To request Lecrolyn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lecrolyn (sodium cromoglicate) differs from antihistamine eye drops by stabilizing mast cells rather than blocking histamine receptors. This mechanism can provide longer‑lasting control of allergic inflammation and is often used when antihistamines alone are insufficient. It is also non‑steroidal, reducing the risk of steroid‑related side effects.

Lecrolyn should be stored below 25 °C, protected from moisture and direct light, and kept in its original container. Do not freeze the solution. If the product appears discolored or contains particles, discard it and obtain a new supply.

Lecrolyn is applied as an ophthalmic solution. The patient instills the prescribed number of drops into the affected eye(s) as directed by the eye‑care professional, typically avoiding contact lens wear during and shortly after administration.

While rare, serious adverse events can include severe allergic reactions such as angioedema of the eyelid, corneal ulceration, sudden vision loss, or anaphylaxis. Patients should seek immediate medical attention if they experience intense pain, rapid vision changes, or signs of a severe eye infection.

Lecrolyn is contraindicated in individuals with a known hypersensitivity to sodium cromoglicate or any component of the formulation. Patients with active ocular infections, recent eye surgery, or those who cannot tolerate the local irritation should discuss alternative therapies with their ophthalmologist.